| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests | Sarah de Crescenzo | 04/08/20 | Boston |
| Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers | Sarah de Crescenzo | 04/08/20 | National |
| Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug | Frank Vinluan | 04/07/20 | Boston |
| Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13 | Editors | 04/07/20 | Boston |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment | Editors | 04/06/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| VenBio Partners Bags $394M to Back More Medicine-Making Biotechs | Sarah de Crescenzo | 04/03/20 | Boston |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies | Sarah de Crescenzo | 04/02/20 | Boston |
| Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic | Frank Vinluan | 04/01/20 | Boston |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments | Sarah de Crescenzo | 03/25/20 | Boston |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic | Sarah de Crescenzo | 03/23/20 | Boston |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders | Sarah de Crescenzo | 03/12/20 | Boston |
| Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline | Sarah de Crescenzo | 03/12/20 | Boston |
| Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO | Frank Vinluan | 03/12/20 | Boston |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data | Frank Vinluan | 03/10/20 | Boston |
| Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data | Sarah de Crescenzo | 03/09/20 | Boston |
| Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod | Frank Vinluan | 03/09/20 | Europe |
